C

China Medical System Holdings Ltd
SWB:2M7C

Watchlist Manager
China Medical System Holdings Ltd
SWB:2M7C
Watchlist
Price: 0.885 EUR -3.8% Market Closed
Market Cap: 3.6B EUR
Have any thoughts about
China Medical System Holdings Ltd?
Write Note

China Medical System Holdings Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

China Medical System Holdings Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
C
China Medical System Holdings Ltd
SWB:2M7C
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
U
United Laboratories International Holdings Ltd
HKEX:3933
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sino Biopharmaceutical Ltd
HKEX:1177
Additional Paid In Capital
¥12.4B
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
28%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Additional Paid In Capital
$1.5B
CAGR 3-Years
2%
CAGR 5-Years
24%
CAGR 10-Years
32%
No Stocks Found

China Medical System Holdings Ltd
Glance View

Market Cap
3.6B EUR
Industry
Pharmaceuticals

China Medical System Holdings Ltd. engages in the production, marketing, promotion, and sale of drugs. The company employs 5,622 full-time employees The company went IPO on 2010-09-28. The firm's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The firm distributes its products within domestic market and to overseas markets.

2M7C Intrinsic Value
1.301 EUR
Undervaluation 32%
Intrinsic Value
Price
C

See Also

Back to Top